[1] 中华医学会血液学分会白血病淋巴瘤学组. 中国嗜酸性粒细胞增多症诊断和治疗指南(2024版)[J]. 中华血液学杂志, 2024, 45: 1-7. doi:10.3760/cma.j.cn121090-20231222-00334. [2] Fulkerson PC, Rothenberg ME. Eosinophil development, disease involvement, and therapeutic suppression[J]. Adv Immunol, 2018, 138: 1-34. doi:10.1016/bs.ai.2018.03.001. [3] Roufosse FE, Goldman M, Cogan E. Hypereosinophilic syndromes[J]. Orphanet J Rare Dis, 2007, 2: 37. doi:10.1186/1750-1172-2-37. [4] Valent P, Klion AD, Roufosse F, et al. Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes[J]. Allergy, 2023, 78: 47-59. doi:10.1111/all.15544. [5] Thomsen GN, Christoffersen MN, Lindegaard HM, et al. The multidisciplinary approach to eosinophilia[J]. Front Oncol, 2023, 13: 1193730. doi:10.3389/fonc.2023.1193730. [6] Eletrebi MM, Sanchez-Ramirez J, Abdalla A, et al. Hypereosinophilia of persistent/unknown cause: a bone marrow-based study integrating WHO-HAEM5 criteria and myeloid next-generation sequencing[J]. Am J Clin Pathol, 2026, 165: aqag031. doi:10.1093/ajcp/aqag031. [7] 韩迎东, 王嵩, 韩欣欣, 等. 25例伴外周动脉闭塞的嗜酸性粒细胞增多症患者临床特点分析[J]. 基础医学与临床, 2023, 43: 785-789. doi:10.16352/j.issn.1001-6325.2023.05.0785. [8] Lefèvre G, Bleuse S, Puyade M, et al. Hypereosinophilia and hypereosinophilic syndromes: first findings from a nationwide multicenter cohort[J]. Allergy, 2025, 80: 1100-1110. doi:10.1111/all.16463. [9] Taurisano G, Ruffi MC, Canalis S, et al. Hypereosinophilia: clinical and therapeutic approach in 2025[J]. Curr Opin Allergy Clin Immunol, 2025, 25: 258-268. doi:10.1097/ACI.0000000000001078. [10] Mattis DM, Wang SA, Lu CM. Contemporary classification and diagnostic evaluation of hypereosinophilia: an ACLPS critical review[J]. Am J Clin Pathol, 2020, 154: 305-318. doi:10.1093/ajcp/aqaa056. [11] Sreedharanunni S, Varma N, Sachdeva MUS, et al. The spectrum of hypereosinophilia and associated clonal disorders -a real-world data based on combined retrospective and prospective analysis from a tropical setting[J]. Mediterr J Hematol Infect Dis, 2018, 10: e2018052. doi:10.4084/MJHID.2018.052. [12] Peju M, Deroux A, Pelloux H, et al. Hypereosinophilia: Biological investigations and etiologies in a french metropolitan university hospital, and proposed approach for diagnostic evaluation[J]. PLoS One, 2018, 13: e0204468. doi:10.1371/journal.pone.0204468. [13] Leurs A, Chenivesse C, Lopez B, et al. C-reactive protein as a diagnostic tool in differential diagnosis of hypereosinophilic syndrome and antineutrophil cytoplasmic antibody-negative eosinophilic granulomatosis with polyangiitis[J]. J Allergy Clin Immunol Pract, 2019, 7: 1347-1351.e3. doi:10.1016/j.jaip.2018.10.002. [14] Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation[J]. N Engl J Med, 1999, 340: 448-454. doi:10.1056/NEJM199902113400607. [15] Rothenberg ME, Hogan SP. The eosinophil[J]. Annu Rev Immunol, 2006, 24: 147-174. doi:10.1146/annurev.immunol.24.021605.090720. [16] Lu L, Lin ZH, Shen RN, et al. Influence of interleukins 3,5, and 6 on the growth of eosinophil progenitors in highly enriched human bone marrow in the absence of serum[J]. Exp Hematol, 1990, 18: 1180-1186. [17] Ogbogu PU, Bochner BS, Butterfield JH, et al. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy[J]. J Allergy Clin Immunol, 2009, 124: 1319-1325.e3. doi:10.1016/j.jaci.2009.09.022. [18] Roufosse F, Kahn JE, Rothenberg ME, et al. Efficacy and safety of mepolizumab in hypereosinophilic syndrome: a phase Ⅲ, randomized, placebo-controlled trial[J]. J Allergy Clin Immunol, 2020, 146: 1397-1405. doi:10.1016/j.jaci.2020.08.037. [19] Kuang FL, Fay MP, Ware J, et al. Long-term clinical outcomes of high-dose mepolizumab treatment for hypereosinophilic syndrome[J]. J Allergy Clin Immunol Pract, 2018, 6: 1518-1527.e5. doi:10.1016/j.jaip.2018.04.033. [20] Kuang FL, Legrand F, Makiya M, et al. Benralizumab for PDGFRA-negative hypereosinophilic syndrome[J]. N Engl J Med, 2019, 380: 1336-1346. doi:10.1056/NEJMoa1812185. |